Inclusion Criteria:  Minimum age 4 weeks old female Or Male GSD1b confirmed by genetic analysis with neutropenia and/or reduced respiratory burst Informed consent signed by the parents/assigns, and the recipient (>13 years old)  Exclusion Criteria:  Risk of non-compliance Chronic renal diseases (eGFR < 60 ml/min/1,73 m2) Active urinary tract infection (temporal criterion, up to recovery) Participation in another clinical trial (minimum 6 months from the end of participation until the date of signing the Informed Consent Form) Participation in therapeutic experiment, in addition to the experimental treatment with empagliflozin (minimum 12 months from the end of participation until the date of signing the Informed Consent Form) Pregnancy, breastfeeding Allergy to Empagliflozin Lack of informed consent